Piper Derek E, Jackson Simon, Liu Qiang, Romanow William G, Shetterly Susan, Thibault Stephen T, Shan Bei, Walker Nigel P C
Department of Molecular Structure, Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California 94080, USA.
Structure. 2007 May;15(5):545-52. doi: 10.1016/j.str.2007.04.004.
Proprotein convertase subtilisin kexin type 9 (PCSK9) has been shown to be involved in the regulation of extracellular levels of the low-density lipoprotien receptor (LDLR). Although PCSK9 is a subtilase, it has not been shown to degrade the LDLR, and its LDLR-lowering mechanism remains uncertain. Here we report the crystal structure of human PCSK9 at 2.3 A resolution. PCSK9 has subtilisin-like pro- and catalytic domains, and the stable interaction between these domains prevents access to PCSK9's catalytic site. The C-terminal domain of PCSK9 has a novel protein fold and may mediate protein-protein interactions. The structure of PCSK9 provides insight into its biochemical characteristics and biological function.
前蛋白转化酶枯草溶菌素9型(PCSK9)已被证明参与低密度脂蛋白受体(LDLR)细胞外水平的调节。尽管PCSK9是一种枯草杆菌蛋白酶,但尚未证明它能降解LDLR,其降低LDLR的机制仍不确定。在此,我们报告了分辨率为2.3埃的人PCSK9晶体结构。PCSK9具有枯草杆菌蛋白酶样的前结构域和催化结构域,这些结构域之间的稳定相互作用阻止了对PCSK9催化位点的访问。PCSK9的C末端结构域具有一种新的蛋白质折叠方式,可能介导蛋白质-蛋白质相互作用。PCSK9的结构为深入了解其生化特性和生物学功能提供了线索。